Stocks and Investing
Stocks and Investing
Tue, December 14, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Luca Issi Maintained (ALLO) at Buy with Decreased Target to $35 on, Dec 14th, 2021
Luca Issi of RBC Capital, Maintained "Allogene Therapeutics, Inc." (ALLO) at Buy with Decreased Target from $45 to $35 on, Dec 14th, 2021.
Luca has made no other calls on ALLO in the last 4 months.
There are 4 other peers that have a rating on ALLO. Out of the 4 peers that are also analyzing ALLO, 2 agree with Luca's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Salveen Richter of "Goldman Sachs" Downgraded from Strong Buy to Hold and Decreased Target to $20 on, Friday, October 8th, 2021
- Benjamin Burnett of "Stifel" Downgraded from Strong Buy to Hold on, Friday, October 8th, 2021
These are the ratings of the 2 analyists that currently disagree with Luca
- Reni Benjamin of "JMP Securities" Maintained at Buy with Decreased Target to $27 on, Tuesday, October 12th, 2021
- Dane Leone of "Raymond James" Upgraded from Hold to Buy and Held Target at $36 on, Friday, September 24th, 2021
Contributing Sources